- Home
- EVMN vs FDUS Comparison
EVMN vs FDUS Comparison
Compare EVMN & FDUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EVMN | FDUS |
|---|---|---|
| Founded | 2020 | 2011 |
| Country | United States | United States |
| Employees | 48 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 869.1M | 719.6M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | EVMN | FDUS |
|---|---|---|
| Price | $13.32 | $19.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 3 |
| Target Price | ★ $43.88 | $21.00 |
| AVG Volume (30 Days) | ★ 1.0M | 317.8K |
| Earning Date | 06-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 11.49% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.65 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.39 |
| Revenue Next Year | N/A | $8.79 |
| P/E Ratio | ★ N/A | $29.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.89 | $16.87 |
| 52 Week High | $33.20 | $22.09 |
Technical Indicators
Market Signals| Indicator | EVMN | FDUS |
|---|---|---|
| Relative Strength Index (RSI) | 29.23 | 57.68 |
| Support Level | N/A | $18.65 |
| Resistance Level | $20.37 | $19.36 |
| Average True Range (ATR) | 1.74 | 0.37 |
| MACD | -0.52 | 0.07 |
| Stochastic Oscillator | 0.59 | 92.97 |
Price Performance
Historical ComparisonAbout EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
About FDUS Fidus Investment Corporation
Fidus Investment Corp is an externally managed, closed-end, non-diversified management investment company that has elected to be treated as a business development company. The company provides customized debt and equity financing solutions to lower middle-market companies. Its investment objective is to provide attractive risk-adjusted returns by generating both current income from debt investments and capital appreciation from equity related investments. The company's portfolio of investment is comprised of securities of companies from different industries such as, Information Technology Services, Business Services, Healthcare Products among others.